Frontiers in pharmacology · 2025
Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Shilong, Lu Yanjun, Xu Chenyang, Liu Huafeng
Аннотация
BACKGROUND: Lung cancer can result in malignant pericardial effusion (MPE), impacting patient prognosis. Intrapericardial infusion of bevacizumab was an alternative treatment for MPE.
CASE PRESENTATION: We present the case of a 48-year-old female with stage IV lung adenocarcinoma and MPE. MPE was managed by intrapericardial infusion of bevacizumab. The first intrapericardial infusion of bevacizumab effectively controlled the MPE for 8 months. Cardiotoxicity quickly emerged after the second intrapericardial infusion of bevacizumab. After intensive treatment, the symptoms of cardiotoxicity resolved within 10 days.
CONCLUSION: The present case indicates that intrapericardial infusion of bevacizumab could lead to cardiotoxicity in MPE patient. Cardiac examinations should be conducted before and after anti-vascular endothelial growth factor treatment.
CASE PRESENTATION: We present the case of a 48-year-old female with stage IV lung adenocarcinoma and MPE. MPE was managed by intrapericardial infusion of bevacizumab. The first intrapericardial infusion of bevacizumab effectively controlled the MPE for 8 months. Cardiotoxicity quickly emerged after the second intrapericardial infusion of bevacizumab. After intensive treatment, the symptoms of cardiotoxicity resolved within 10 days.
CONCLUSION: The present case indicates that intrapericardial infusion of bevacizumab could lead to cardiotoxicity in MPE patient. Cardiac examinations should be conducted before and after anti-vascular endothelial growth factor treatment.